AstraZeneca CFO Aradhana Sarin (L) and CEO Pascal Soriot at the company's investor day (Ayisha Sharma for Endpoints News)
May 21, 2024 11:16 AM EDTUpdated May 21, 09:14 PM
R&D
Pharma

As­traZeneca counts on ‘dif­fi­cult-to-copy’ ther­a­pies for big 2030 goal and be­yond

Ayisha Sharma

News Reporter

Amber Tong

CAM­BRIDGE, UK — Pas­cal So­ri­ot has set an am­bi­tious $80 bil­lion rev­enue tar­get for As­traZeneca by 2030. But he’s not stop­ping there. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times